TrialBreast cancer (Tokyo, Japan)2018

Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial.

N Masuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.